Ticagrelor: A Potent anti-Platelet for Acute Coronary Syndrome
Ticagrelor is a P2Y12 inhibitor used to reduce the risk of cardiovascular events like heart attacks and stroke in patients with acute coronary syndrome (ACS). It prevents the platelets from clumping together and forming clots, which can block the blood flow to the heart or brain. It also minimizes the risk of stent thrombosis in patients who have undergone stent placements.
Mechanism of Action
Ticagrelor inhibits the P2Y12 receptor on platelets, which reduces their ability to activate and aggregate. This action helps prevent the formation of blood clots that could lead to serious cardiovascular events.
Indications
● Acute Coronary Syndrome (ACS): To reduce the risk of heart attacks and strokes.
● Post-Stent Implantation: To prevent thrombosis (clot formation) after coronary stenting.
Dosage and Administration
● Loading Dose: 180 mg once, followed by 90 mg twice daily.
● Long-term Maintenance: 90 mg twice daily.
● Pediatric dose: Safety and efficacy have not been established.
Side Effects
● Common: Shortness of breath, dizziness, and bleeding.
● Serious: Major bleeding, bradycardia (slow heart rate).
Pregnancy Category: Category C – Use with caution during pregnancy.
Common Brands
● Brilinta, Axcer.
